CAS: 17997-47-6; 2-(Tributylstannyl)Pyridine

相似化合物

301652-23-3 189195-41-3 259807-95-9

上下游产品

CAS号109-04-6 2-溴吡啶 | CAS号1461-22-9 三丁基氯化锡 | CAS号56-35-9 三丁基氧化锡 | CAS号17624-36-1 2-pyridyllithium | CAS号380917-97-5 吡仑帕奈 | CAS号391604-55-0 2-(2,4-二氟苯基)吡啶 | CAS号381233-78-9 5-(2-吡啶基)-1,2-二... | CAS号141855-74-5 N,N-diethyl-4-(... | CAS号199383-71-6 3-(diethylamino... | CAS号142672-91-1 triphenyl-(2-py... | CAS号4373-60-8 2-(3-溴苯)吡啶 | CAS号189090-31-1 2-(8-pyridin-2-... | CAS号205052-97-7 6-BROMO-4-NITRO... | CAS号179873-48-4 [2,2'-联吡啶]-5-甲醛

2-氨基吡啶置于正丁基锂,氢溴酸,溴,Sodium Nitrite体系中,用 四氢呋喃,水 用作溶剂,化学反应 2.83H,反应生成三正丁基2-吡啶基锌
参考文献:氘代vismodegib改善药代动力学性质的设计,合成及生物学评价
标题:氘代vismodegib改善药代动力学性质的设计,合成及生物学评价
摘要:Vismodegib是一种口服和高选择性刺猬(hh)抑制剂,用于治疗基底细胞癌(bcc).在这项工作中,制备了在某些代谢活性位点上具有氘代氢取代作用的vismodegib类似物,并发现其在小鼠中具有更好的药代动力学特性.特别是,氘代化合物sklb-C2211与原型相比明显改变了血液循环行为,这可以通过明显延长血液循环半衰期(t 1/2)和增加auc 0->∞来证明.这些结果表明sklb-C2211有可能成为hh信号通路的长效抑制剂,并为进一步研究其可药用性奠定了基础.
Doi:10.1016/j.Bmcl.2018.06.025

专利信息

专利号:US-2024335442-A1
优先权日:2021-08-02
标 题:N-acylhydrazone compounds capable of inhibiting nav1.7 and/or nav1.8, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
发明人：BARREIRO GABRIELA; SANT'ANA DANILO PEREIRA DE; GAMBA LUIS EDUARDO REINA; FRAGA CARLOS ALBERTO MANSSOUR; BARREIRO ELIEZER JESUS DE LACERDA; LIMA LÃ?DIA MOREIRA
权利人:EUROFARMA LABORATORIOS S A; UNIV FEDERAL DO RIO DE JANEIRO UFRJ
摘要:N-acylhydrazone compounds that are Nav 1.7 and/or Nav 1.8 inhibitors, including N-acylhydrazone compounds of Formula (I), wherein the substituents R1 to R6 are independently selected from the groups defined in the specification, as well as to the processes for the preparation thereof, compositions comprising at least one of said compounds, uses, treatment methods for treating or preventing pain-related pathologies, and kits, and which are applicable in the fields of medicinal chemistry and organic synthesis, as well as in the treatment of pain-related disorders.

专利号:WO-03061385-A1
优先权日:2002-01-17
标题:Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents
发明人：AN HAOYUN; HONG ZHI; SMITH KENNETH; DING YILI; GIRARDET JEAN-LUC
权利人:RIBAPHARM INC; AN HAOYUN; HONG ZHI; SMITH KENNETH; DING YILI; GIRARDET JEAN-LUC
摘要:Tricyclic nucleoside libraries and library compounds are prepared using combinatorial chemistry and non-combinatorial chemistry methods. Contemplated library compounds are particularly useful in inhibition of viral propagation, and particularly of viral propagation of the HCV virus.

专利号:BR-112016017679-B1
优先权日:2014-02-21
标题 :5-BENZYLISOQUINOLINE DERIVATIVE COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, PROCESS FOR THE SYNTHESIS OF SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM

专利号:CN-112387313-B
优先权日:2020-11-17
标题:Tridentate phenanthroline manganese catalyst and its application in the synthesis of organosilicon/boron compounds

专利号:WO-2023109870-A1
优先权日:2021-12-15
标 题:Pyrazolopyrimidine compound and use thereof
发明人：YE BIN
权利人:SHANGHAI YIDI BIOTECHNOLOGY CO LTD
摘要:The present invention belongs to the field of drug synthesis, provides a pyrazolopyrimidine compound and the use thereof, and specifically relates to a pyrazolopyrimidine compound as shown in formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and/or the pharmaceutically acceptable salt thereof, a method for preparing the compound, and the use of the compound in the preparation of a drug for treating related diseases mediated by PI3K.

专利号:US-7737166-B2
优先权日:2005-08-17
标 题:Antifungal bicyclic hetero ring compounds
发明人：KAWAKAMI KATSUHIRO; KANAI KAZUO; HORIUCHI TAKAO; TAKESHITA HIROSHI; KOBAYASHI SYOZO; SUGIMOTO YUICHI; ACHIWA ISSEI; KUROYANAGI JUNICHI
权利人:DAIICHI SANKYO CO LTD
摘要:A 1,6-β-glucan synthetase inhibitor is provided, having potent growth inhibition and having excellent safety. A compound is provided, capable of expressing in a wide spectral range and specifically or selectively, an antifungal effect based on its functional mechanism of 1,6-β-glucan synthesis inhibition. Also provided is a drug, a salt or hydrate thereof, especially an antifungal that contains the compound. Concretely, provided is a compound of the following formula (I), its salt or hydrate, and a drug or antifungal containing, as the active ingredient, the compound, its salt or hydrate: